Cambrex, a leading global contract development and manufacturing organization, is celebrating the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient manufacturing facility in High Point.
Cambrex, a leading global contract development and manufacturing organization (CDMO), celebrated this week the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point.“We are extremely excited about this expansion in North Carolina, which would not have been possible without the support of the state’s leadership and economic development programs, and their focus on nurturing the region’s skilled and diverse workforce,” said Dan Bowles, Vice President and General Manager, Cambrex High Point.
Cambrex today announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina. This expansion doubles the facilitys manufacturing